Jump to main content
Jump to site search


A luminescent biosensor for ex vivo detection of HER2-positive breast cancer based on a novel affiprobe

Author affiliations

Abstract

A novel receptor tyrosine-protein kinase erbB-2 (HER2)-binding affiprobe – named ZHER2:342-RLuc – was designed, produced and assessed in terms of function to detect HER2 positive cells and for preliminary clinical diagnosis. The ZHER2:342 affibody with affinity for HER2 was fused to Renilla luciferase, and the purified affiprobe was used for detection of HER2 positive cells as well as evaluation of surgical specimens from breast cancer patients. The results showed that the affiprobe can specifically bind to HER2 positive cells, and therefore, it may be used for molecular detection.

Graphical abstract: A luminescent biosensor for ex vivo detection of HER2-positive breast cancer based on a novel affiprobe

Back to tab navigation

Supplementary files

Publication details

The article was received on 22 May 2019, accepted on 24 Jul 2019 and first published on 26 Jul 2019


Article type: Communication
DOI: 10.1039/C9AY01077G
Anal. Methods, 2019, Advance Article

  •   Request permissions

    A luminescent biosensor for ex vivo detection of HER2-positive breast cancer based on a novel affiprobe

    M. Nazari, R. Emamzadeh, A. Minai-Tehrani, M. Nasir shirazi and A. Naimi, Anal. Methods, 2019, Advance Article , DOI: 10.1039/C9AY01077G

Search articles by author

Spotlight

Advertisements